Your session is about to expire
← Back to Search
Neural Interface System
BrainGate2 System for Quadriplegia (BG-Speech-01 Trial)
N/A
Recruiting
Led By Jaimie Henderson, MD
Research Sponsored by Leigh R. Hochberg, MD, PhD.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants with a diagnosis of ALS with anarthria, or severe dysarthria with decline in the preceding four months.
Participants must have a diagnosis of amyotrophic lateral sclerosis (ALS) as verified by a clinical expert in neurologic diseases.
Must not have
Complete or incomplete tetraplegia (quadriplegia)
Between 18 and 80 years of age.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at participant exit from study, or up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to show that people with tetraplegia can use their thoughts to control a computer and other devices, increasing independence.
Who is the study for?
This trial is for adults aged 18-80 with tetraplegia due to conditions like ALS, spinal cord injury, or stroke. They must be unable to speak clearly or at all but have one reliable way to communicate. Participants should live within a three-hour drive of the study site and are expected to survive more than six months.
What is being tested?
The BrainGate2 Neural Interface System is being tested for its safety and ability to let people with severe paralysis control a computer cursor and other devices using their thoughts alone.
What are the potential side effects?
As this trial tests a neural interface system, potential side effects may include discomfort at the implantation site, headache, infection risk from surgery, and possible device-related complications.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have ALS and cannot speak or have severe speech difficulties that have worsened recently.
Select...
I have been diagnosed with ALS by a neurology specialist.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have paralysis that affects all four of my limbs.
Select...
I am between 18 and 80 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at participant exit from study, or up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at participant exit from study, or up to 5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Device Safety
Secondary study objectives
Device Feasibility
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: BrainGate Neural Interface SystemExperimental Treatment1 Intervention
Placement of the BrainGate2 sensor(s) into the speech-related cortex
Find a Location
Who is running the clinical trial?
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
353 Previous Clinical Trials
181,475 Total Patients Enrolled
7 Trials studying Amyotrophic Lateral Sclerosis
175 Patients Enrolled for Amyotrophic Lateral Sclerosis
Leigh R. Hochberg, MD, PhD.Lead Sponsor
3 Previous Clinical Trials
19 Total Patients Enrolled
3 Trials studying Amyotrophic Lateral Sclerosis
19 Patients Enrolled for Amyotrophic Lateral Sclerosis
Jaimie Henderson, MDPrincipal InvestigatorStanford University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have ALS and cannot speak or have severe speech difficulties that have worsened recently.I can communicate clearly or have a reliable way to communicate.I have been diagnosed with ALS by a neurology specialist.I have paralysis that affects all four of my limbs.Your doctor believes you will live for at least 6 more months.I am between 18 and 80 years old.
Research Study Groups:
This trial has the following groups:- Group 1: BrainGate Neural Interface System
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger